INTRODUCTION AND OBJECTIVES: Contralateral recurrence after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) is rare and difficult to manage. Clinicians and patients are faced with the difficult decision of balancing oncologic control while preserving renal function. We report our experience on management and outcomes of contralateral recurrence in patients after RNU for UTUC.
METHODS: Between 1995 and 2009 we retrospectively reviewed 480 patients who underwent RNU at Mayo Clinic. We identified 21 (4.3%) patients who developed UC recurrence in the contralateral system following initial RNU. Patients with metastatic disease before or at the time contralateral recurrence and patients with non-UC primary tumors were excluded. Charts were retrospectively reviewed. Progression to metastatic disease from the time of contralateral recurrence was investigated as the primary outcome of interest.
RESULTS: The median age of the cohort was 72 years. Of the 21 patients, 14 (70%) were male, 19 (91%) were smokers, 13 (62%) had a history of bladder cancer and 10 (77%) had previously undergone a cystectomy. The urine cytology was positive in 15 (71%) prior to the initial RNU. During the initial RNU, 17 (81%) had non-muscle invasive disease; 10 (48%) had high grade pathology; 7 (33.3%) had concomitant CIS and 10 (48%) had multifocal disease. Median time to contralateral recurrence from the initial RNU was 12 months. Over a median follow up of 42 months, the overall median number of endoscopic procedures to manage contralateral recurrence was 3 (IQR 2, 4.5). 11 (52%) patients had intrapelvic instillation either via a nephrostomy tube or reflux through a stent. 6 (29%) patients eventually underwent definitive treatment with a second RNU. Of these, 5 had attempts at endoscopic control before second RNU; and the median number of endoscopic procedures was 2. The 3-year metastasis free survival was 68% and there was no statistically significant difference in progression to metastatic disease between patients undergoing RNU and those managed with only endoscopic approach (p¼0.31). Progression to metastasis was seen more frequently in patients with a history of bladder cancer (p¼0.01).
CONCLUSIONS: Approximately, 5% of patients with UTUC following RNU develop contralateral recurrence. Patients with a history of bladder cancer who develop contralateral recurrence are more likely to die of metastatic disease. Therefore, more studies are needed to elucidate the role of early definitive treatment in this unique patient population. INTRODUCTION AND OBJECTIVES: Intravesical recurrence after radical nephroureterectomy (RNU) ranges from 15% to 50%. However, only a few studies have investigated pathologic characteristics of bladder tumor recurrence, and even fewer have evaluated risk factors for muscle invasive bladder cancer (MIBC) after RNU for primary treatment of upper tract urothelial carcinoma (UTUC). Therefore, we present our data on the clinical course of intravesical recurrence and pathologic features for MIBC following RNU.
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METHODS: Between 1995 and 2009 we identified 395 patients who underwent RNU at Mayo Clinic for urothelial carcinoma. We identified 113 patients who subsequently developed intravesical recurrence. Patients with a prior radical cystectomy were excluded. Charts were retrospectively reviewed. Kaplan Meier analysis and Cox Proportional hazard regression models were used to estimate predictors and the risk of intravesical recurrence and MIBC from the time of RNU. RESULTS: Of the 395 patients, 28.6% (113) developed intravesical recurrence and 4.5% (18) had MIBC following RNU. Over a median follow up period of 43.4 months, 18.5% (21) of patients underwent radical cystectomy for intravesical recurrence; of these 52% (11) was for MIBC. Median time to intravesical recurrence was 7.8 months and median time to development of MIBC was 17.9 months. The 5-year probability of developing intravesical recurrence was 37.5%; while the 2, 5, and 10-year estimates of MIBC were 1.1%, 6.0%, and 6.7%, respectively. The 5-year cancer specific survival for patients who developed intravesical recurrence and MIBC after RNU was 86.1% and 65.2%, respectively (p¼0.01). Specifically, high grade pathology, ureteral tumors and concomitant CIS were associated with an increased risk of MIBC (HR 3.4, p¼0.01; HR 6.7, p<0.01; and HR 2.7, p¼0.05; respectively) INTRODUCTION AND OBJECTIVES: Conventional transurethral resection of bladder tumor (TURBT) with white light cystoscopy (WLC) has recognized shortcomings including missed small tumors, inadequate assessment of resection margins and depth, and difficulty in differentiating cancerous from benign lesions. These limitations contribute to cancer recurrences and compel the need for repeat TURBT to ensure adequate cancer staging. Adjunctive optical imaging technologies including photodynamic diagnosis (PDD), narrow band imaging (NBI), and confocal laser endomicroscopy (CLE) improve Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1371
